0:00:23Good evening once again. I'm really glad that I can talk more about Caversoft because
0:00:27it's really hard to tell you everything in two minutes. So, thank you.
0:00:31And now I would like to go more scientific.
0:00:35As I already told you, protein structures are extremely complex and they consist of hundreds
0:00:44of thousands of atoms basically; and they are long, long chains of amino acids folded
0:00:50together in a specific shape. And it's really difficult to explore them without proper visualization.
0:00:56So, the scientists, they look for specific spots inside the protein structure, which is, which
0:01:03are deeply buried and these sites are called active sides. They are reactive.
0:01:11And when a ligand, a small molecule, is deployed into the structure to the active
0:01:18side, a reaction occurs
0:01:20and some products
0:01:23are born, and these products are basis of a new medicine or a new chemical
0:01:29compound of some kind.
0:01:30So,
0:01:32n fact, the protein is a factory for our products, and the goal of protein
0:01:37engineering is to develop the factory.
0:01:43What we do is detect tunnels
0:01:45specific pathways inside the protein structure,
0:01:49so you can imagine it like a mouse drilling holes into a block of cheese.
0:01:54And we search, of course, for the widest pathways for the, for the shortest pathways.
0:02:00And there are also a lot of chemical characteristics involved.
0:02:06So, our software not only enables you to compute these pathways, but it enables you
0:02:13to evaluate the big data, the big results, immediately and to visualise them.
0:02:19Now let's move to another level. The proteins are not static structures, they move in
0:02:25time, they are they are influenced by their surroundings. And you can imagine how it's
0:02:31hard for the mouse to drill holes there are moving in the cheese. So, what
0:02:36are the biochemists interested in is, in fact, the stability of these pathways in time,
0:02:43how they change, if they appear long enough to the ligand
0:02:47is able to penetrate inside the protein.
0:02:51These properties you can, you can see, you can evaluate by using various graphs and
0:02:58teeth plots.
0:03:02Other, I said,
0:03:03is that our software is able to process big structures containing of, consisting of thousands,
0:03:12hundreds of thousands of atoms like this ribosome complex.
0:03:18Now, let's get some hard data.
0:03:21Our customers can be divided into two groups. The first is commercial organisations like pharmaceutical
0:03:28and biotech companies, and also contract research organisations. Then there is the academia.
0:03:36To get more users attracted to our software, we plan to provide the software for
0:03:44free. The basic version of our software for free for the noncommercial academia.
0:03:52Now our revenue will come from a newer licenses, to be able to react to
0:03:58recent trends in the field, because the development is quite quick.
0:04:03Of course, we will continue to develop new methods and we will provide our customers
0:04:09with upgrades.
0:04:11Very important is to provide scientific support to get the project
0:04:15customised for specific, for specific research. And to also, when we have the capacity, we
0:04:22will try to, we will try to develop new analytical methods on demand.
0:04:30So now, as I said, we have a beta version ready and the first, first
0:04:36part of next year, we plan to have a commercial product ready And we hope
0:04:41to have first licenses sold next year,
0:04:45in the second half.
0:04:48In the meantime, we will, of course, continue to develop our software, enhance old mentors
0:04:54and develop new ones.
0:04:57Now let me briefly introduce our team.
0:05:00Uur CEOs, we call them bosses, but they are more like advisory board, are professor
0:05:07Jiri Damborsky and associate professor Jiri Sochor. They are experts in the fields of bioinformatics
0:05:13and computer science. Then there is six of us.
0:05:17Researchers and developers. And then there is, wow, he's huge.
0:05:22Ondrej Valina
0:05:25who
0:05:27who will take care of marketing and sales. So, thank you for your attention and
0:05:34I wish you a pleasant evening.
0:05:44All right. We tend to go down this path the beginning of each time.
0:05:48Pricing.
0:05:50How much does this cost? So, we have been thinking about
0:05:54a few models, but the basic one is the annual license, which will cost ten
0:06:00thousand euros.
0:06:01So you get the software package and you get the support for one year for
0:06:08ten thousand euros.
0:06:09But maybe this is a little price for big companies and it's a killing price
0:06:16for a startup. So, we were also thinking about some
0:06:21time
0:06:23time-limited version of our product.
0:06:28I am... sorry, sorry.
0:06:29Surprised every time I'm talking to this thing. What is the difference between the free
0:06:34version and this, and the paying version? Like, why would I buy the ten thousand
0:06:40euro version, if I can have a free one?
0:06:44The free one you cannot use when you are performing commercial research. This will be
0:06:51licensed, so if you are non-commercial academia, you use it for educational purposes, you don't
0:06:57have to pay for it.
0:06:59We hope these people, when they later come to... But, I, it's just that I
0:07:05don't have the rights even though I might do it or is there like an
0:07:08actual, like
0:07:10extra... Like, my point is that, you know, I can, you can tell me don't
0:07:14use it commercially and I might still do it, because
0:07:17Is there any software difference at all or...? Okay, you won't be able to process
0:07:23a huge data and you won't be able to evaluate them using those graphs. For
0:07:29example, useful on the slides. So we really, really cut off version of this software.
0:07:36Okay, so it's free try-out for small data just to get a hand and then...
0:07:40Yes. Okay. Yes, you can, you can try the features, you can try everything and
0:07:44then you are able to buy the full version.
0:07:48This is great and none of us really understands the area
0:07:52that you're talking about. But, anyway, maybe you can tell us are you unique in
0:07:56what you do? Is there any competition? What are they standing for? So, yes, there
0:08:02is competition in the academia, but these are projects really developed as a part of
0:08:09some research. Most of them are discontinued and none of them is commercial now.
0:08:17Moreover, we are the first ones who come up with this solution and iIm proud
0:08:23to say that we are the most precise. The probability of our analysis is the
0:08:28highest.
0:08:29Which is also well published in our, in our articles.
0:08:34It sounded like you're currently in beta. Do you have any beta testers or...? Yes,
0:08:38of course.
0:08:38The first ones we incorporated directly with a protein engineering group here in Brno.
0:08:45And of course, this group has some friendly research labs,
0:08:51who will also performe beta testing of our product. So,...
0:08:58Is there any intellectual property that can be patented?
0:09:01Well, of course we are thinking about it, but to patent a software its quite
0:09:08impossible in Czech Republic. So maybe there is some other, other way to do this
0:09:15by patenting the technology, the algorithms and application of them. So yes, we are thinking
0:09:23about it, really.
0:09:26Hi. In your previous presentation, the first one, you mentioned you have already some interested
0:09:31parties, some interested companies and universities. How many licenses are you hoping to sell next
0:09:37year then?
0:09:38That's quite hard to say, but to we hope to sell
0:09:44ten to twenty licenses
0:09:47that will be really great.
0:09:51Thank you for questions.
0:09:54Hi. I have the last question. You were talking about commercialisation second quarter of 2012,
0:10:00is it right? First quarter. First quarter of 2013, okay. Because... okay, first quarter is
0:10:07not that far then. Beause my question is do you need money? Because, you know,
0:10:12it's something like, it's still far away and you know when you stretch the time
0:10:17where you actually sell something, sometime you may, you know, you may fall back by
0:10:21lack of money. So, are you guys on the good path? Do you need money
0:10:25today? Well, actually we can survive without money
0:10:30but, as you know,
0:10:35we can survive, that's the important part. Okay. So if everything goes as planned, we
0:10:43will have the commercial version in January, February. Okay, it's not too far, fair enough.
0:10:48So maybe it's good to say that
0:10:52the testing has to be really precise, the chemists have to cook the protein, test
0:10:57it if it's relevant, and then publish the results. That's what's important for the big
0:11:01companies. My last question. Can I just last one... sorry. I mean, if you were
0:11:07ready in January, do you have people who are really already ready to commit to
0:11:11buy the product today?
0:11:14Well, as you saw, these companies, they contacted us directly if we have a commercial
0:11:21license for them. So we told them to wait until the first quarter, so... Thank
0:11:25you very much. Thank you for the question.